Appeals Court Confirms Conviction of Intercos Korea in Kolmar Korea Tech Theft
Kolmar Korea (KRX: 161890) has won the victory in the remand trial against Intercos Korea, the Korean subsidiary of Italian cosmetics firm Intercos, concerning the misappropriation of its core sunscreen technology. The latest ruling has confirmed Intercos Korea is guilty of stealing Kolmar Korea’s technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113259255/en/
Kolmar Korea R&D Complex (photo: Kolmar Holdings)
The 3-2 Criminal Division of the Suwon District Court sentenced a fine of KRW 5 million on Intercos Korea for breaching the Unfair Competition Prevention and Trade Secret Protection Act on October 18. While the court reduced the fine from an initial KRW 10 million to KRW 5 million, it upheld the conviction of Intercos Korea. The ruling became final as Intercos Korea opted not to file an appeal.
Intercos Korea was alleged to have recruited “A”, a former Kolmar Korea employee, in order to acquire Kolmar’s sunscreen technology unlawfully. Joining Kolmar Korea since 2008, “A” had been in charge of research and development of sun care products. He suddenly resigned in 2018 due to immigration to the U.S. However, it was found that he joined Intercos Korea just one week after his departure. In the process, he reportedly leaked hundreds of Kolmar Korea's confidential documents via Google Drive.
Intercos Korea's sales of sun care products surged after “A” joined the company. Intercos Korea had no record of selling any UV protection products in 2017. However, it began selling sun care products after 2018 when “A” left Kolmar. The prosecution conducted a digital forensic analysis on the laptop used by "A", thereby uncovering evidence of his criminal activities.
In August 2021, the Suwon District Court sentenced “A” to ten months in prison. Additionally, “B”, an accomplice in the fraudulent activities, received a six-month sentence suspended for two years, and Intercos Korea was fined KRW 5 million. The appeal court reaffirmed the prison sentence for “A” and increased the fine for Intercos Korea to KRW 10 million.
“A” appealed the lower court’s decision, but the Supreme Court upheld the ten-month prison sentence, rendering the decision final. However, the Supreme Court found that the portion of the second trial decision imposing a KRW 10 million fine on Intercos Korea required further review and remanded it to the Suwon District Court. This decision was based on the Supreme Court’s finding that penalizing the company under joint penalty provisions for the "attempted" act of former employee “A” was unjustified.
In the subsequent retrial, the court recognized the harm suffered by Kolmar Korea. Although the fine against Intercos Korea was reduced due to the absence of legal grounds to penalize a juridical person for a “failed attempt”, the court maintained the conviction.
An official from Kolmar Korea said, "Intercos Korea is now proven guilty of misappropriating Kolmar Korea’s sun care technology. Hopefully, other Korean companies with world-class technologies will not face similar harm.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113259255/en/
Contacts
Kolmar Holdings
Jang-Woo Lee
jay.lee@kolmar.co.kr
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 14:05:00 CET | Press Release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au
Ant Group Announces Major Upgrades to Its 15-Million-MAU AI Health App AQ Amid Wider Push into Health Sector15.12.2025 14:03:00 CET | Press Release
Ant Group today announced major upgrades to its AI health app AQ, with a new Chinese name “Ant A-Fu.” The character “Fu” conveys good wishes and well-being, reflecting the app’s goal to promote better health and quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215203213/en/ Ant Group’s AI health app AQ features three core capabilities: health Q&A, AI health companion, and integrated health services. The upgraded version of AQ now features three core capabilities: health Q&A, AI health companion, and integrated health services. Launched in June 2025, AQ has rapidly grown to 15 million monthly active users, making it China’s leading AI health management app. Positioned as an AI health companion service, AQ currently answers over 5 million health-related questions every day. The announcement comes amid China’s ongoing demographic shift. According to projections from the National Health Commission, by around 20
Copeland and Daikin Cooperation Brings Solutions to European Customers15.12.2025 14:00:00 CET | Press Release
Copeland and Daikin, two global leaders in heating, ventilation and air conditioning (HVAC) solutions, today announced the expansion of their existing joint venture into Europe. Through this cooperation, the companies will introduce advanced inverter swing rotary compressors, power electronics and controls designed specifically for European residential heat pumps. This collaboration underscores both companies’ commitment to accelerate the energy transition, with heat pumps recognized by industry reports as a cornerstone technology helping to reduce global carbon dioxide emissions by an estimated 500 million tons by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215625806/en/ (Left to right) Ross B. Shuster, CEO of Copeland and Jiro Tomita, executive associate officer of Daikin As Europe rapidly transitions away from fossil fuels, the demand for residential heat pumps is growing in parallel with ambitious sustainabil
Visa Unveils New Global Stablecoins Advisory Practice15.12.2025 13:00:00 CET | Press Release
Visa (NYSE: V), a global leader in digital payments, today announced the launch of its Stablecoins Advisory Practice. The new value-added service offering by Visa Consulting & Analytics (VCA) provides actionable insights and recommendations to guide banks, fintechs, merchants, and businesses of all sizes on market fit, strategy, and implementation. As the stablecoin market cap surpasses $250 billion, Visa’s settlement volume has accelerated, reaching a $3.5 billion annualized run rate as of November 30. Businesses are turning to Visa’s new Stablecoins Advisory Practice to unlock growth opportunities. “Putting our members first has always been our mission, and we’re committed to exploring innovations that strengthen financial health and convenience for those we serve. Stablecoins may represent an opportunity to enhance speed and lower cost in payments, so with the support of Visa, we are evaluating how this technology could fit into our broader strategy to deliver meaningful value to ou
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press Release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom